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The concept of ideal cardiovascular (CV) health, with
emphasis on the prevention of CV disease (CVD), was included by the American Heart Association (AHA) among its
strategic goals for 2020 [1]. This concept was intended to
focus mainly on the promotion of a healthy lifestyle and the
adoption of a multifactorial intervention with nonpharmacological or pharmacological means, aiming at the
prevention or the effective control of CVD risk factors [1].
Ideal CV health is defined as optimal levels of 3 CVD risk
factors [blood pressure (BP), fasting plasma glucose and
total cholesterol) and 4 behaviours [body mass index (BMI),
smoking, physical activity and healthy diet] [1]. These 7
ideal CV metrics, called life's simple 7, are probably the best
available markers of life-time CVD risk [2]. Recent studies
have shown that the levels of ideal CV health in the United
States to be very low at a community level [3-5] and to be
associated with cardiac events [3], stroke [2] and total mortality [6]. A large study was conducted in 5,785 young adults
(20-39 years old) from 5 international populations: the Minneapolis Childhood Cohort Study, the Princeton Follow-up
Study, the Bogalusa Heart Study, the Cardiovascular Risk in
Young Finns Study, and the Childhood Determinants of
Adult Health (CDAH) Study; all members of the International Childhood Cardiovascular Cohort (i3C) Consortium
[7]. Results of the study showed that ideal CV health, as defined by the AHA, was rare among young participants of the
study. An amazingly low (only 1%) percentage of the participants had all 7 health metrics in the 5,785 young adults
participating from all international cohorts [7]. Many of the
participants had ideal glucose (73%), cholesterol (64%), and
were non-smokers (64%); diet (7%) was the least common
metric for participants from any of the cohorts [7]. The lowest prevalence of a clinical CVD risk factor from the life's 7
simple was BP; this was normal in only 52% of the
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participants [7]. The National   and Nutrition Examination Surveys (NHANES) 2003-2008 evaluated the prevalence of the 7 CV health metrics in 14,515 adults [8]. Participants were stratified in young (20-39 years), middle-aged
(40-64 years) and elderly (65 years). Less than 1% of subjects exhibited   CV   for all 7  . Among
CV   behaviors, non-smoking was the most prevalent
(60.2-90.4%),   Healthy Diet Score was least prevalent
(0.2-2.6%) across groups, while    (36.5-45.3%)
and   physical activity levels (50.2-58.8%) were higher
in young adults compared with middle-aged or elderly [8].
  total cholesterol (23.7-36.2%), blood pressure (11.9%16.3%), and fasting blood glucose (31.2-42.9%) were less
frequent in older adults compared with young and middleaged adults. The prevalence of poor CV   status was
lowest in young age compared with higher middle and older
ages [8]. Again, ideal BP was the least prevalent among
clinical CVD risk factors [8].
A relevant Chinese study included 91,698 participants
(72,826 men, age 18-98 years-old), free of myocardial infarction and stroke at baseline (2006-2007) [2]. The hazard
ratios (HR) and 95% confidence interval (CI) for total stroke
according to the adherence to life's 7 simple [0 (reference), 1,
2, 3, 4, 5, and 6/7 ideal CV metrics] were: 1, 0.92 (0.691.23), 0.69 (0.52-0.92), 0.52 (0.39-0.68), 0.38 (0.28-0.51),
0.27 (0.18-0.40), and 0.24 (0.11-0.54), respectively (p for
trend <0.01), after adjusting for age, sex, education, income
and hospital [2]. Similar inverse associations were observed
for both ischaemic and haemorrhagic stroke (p for trend
<0.01) [2]. In this study, high BP played a major role in
stroke incidence [2].
The above data suggest that in the effort of achieving
ideal CV health, hypertension should be one of the primary
targets, because of its high prevalence in the general population and the low levels of effective control [9]. Moreover, if
we can control BP and improve some of the other CV metrics of ideal CV health, this will have significant additive
beneficial effects.
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Non-pharmacological interventions to control hypertension or to augment the effects of antihypertensive drug
treatment (thereby potentially reducing the need for more
drugs), have been used for a long time [10,11]. The recent
(2013) ESH/ESC Guidelines for the management of hypertension [12] suggest: salt restriction to 5-6 g/d, moderation of
alcohol consumption to <20-30 g/d of ethanol in men and
<10-20 g/d in women, increased consumption of vegetables,
fruits, and low-fat dairy products, reduction of BMI to <25
kg/m2 and of waist circumference to <102 cm in men and
<88 cm in women, regular exercise (at least 30 min of moderate dynamic exercise on 5 to 7 days per week), and advice/support for smoking cessation [12]. Moreover, high
quality evidence suggests that increased potassium intake is
beneficial in most adults without impaired renal handling of
potassium for the prevention or control of elevated BP and
prevention of stroke (reduction of incidence by 24%), without adverse effects on lipid concentrations, catecholamine
concentrations or renal function [13]. However, compliance
to long-term lifestyle changes to treat hypertension is very
low, and special programs and interventions to improve this
adherence may need to consider the existing barriers [14]. A
low desire, interest or awareness are commonly reported
barriers to salt restriction, changes in diet, weight loss, smoking cessation and alcohol reduction [14]. In contrast, the
most common barrier to engaging in physical activity to
regulate BP is time limitations and the challenge of managing a co-existing physical condition/disease; arthritis (60%),
back problems (41%), diabetes (27%), CVD or stroke (27%),
asthma (23%) and chronic obstructive pulmonary disease
(22%) [14]. Thus, non-pharmacological interventions for the
treatment of hypertension are not successful enough [15].
A number of studies have demonstrated the protective effects of foods rich in polyphenols (fruit, tea, wine and cocoa
or chocolate and especially citrus fruit) against several CVD
risk factors such as hypertension, low density lipoprotein
(LDL) particle oxidation and endothelial dysfunction [1618]. The pomegranate tree (Punica granatum), considered to
be originated in the Garden of Eden (modern Mesopotamia
and specifically Iran), has been extensively used as a folk
medicine in many cultures [19]. Today, it is widely cultivated throughout the Mediterranean region of southern
Europe, the Middle East and the Caucasus region, northern
and tropical Africa, the Indian subcontinent and the drier
parts of Southeast Asia [19]. Introduced into Latin America
and California by Spanish settlers in 1769, pomegranate is
also cultivated in parts of California and Arizona. Edible
parts of pomegranate fruits (about 50% of total fruit weight)
comprise 80% juice and 20% seeds. Fresh juice contains
85% moisture, 10% total sugars, 1.5% pectin, ascorbic acid
and polyphenols [19]. Pomegranate fruit is considered as a
heart-healthy fruit [19,20]. Pomegranate is rich in polyphenolic-type antioxidants, including tannins, anthocyanins and
several other types of flavonoids [20,21]. The soluble polyphenol content in pomegranate juice (PJ) normally ranges
between 0.2 and 1.0% depending on the fruit variety, and
mainly comprises tannins, ellagic anthocyanins, catechins,
and gallic and ellagic acids [20,21]. Despite the previously
reported CV health benefits of pomegranate and its high content in polyphenols and flavonoids [20-22], there have been
very few studies on the anti-hypertensive effects of PJ [23].
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A very recent study included 21 hypertensive patients (aged
30-67 years) [23]. These were assigned to receive either PJ
(150 ml/day in a single occasion between lunch and dinner; n
= 11) or the same amount of water (n = 10) for a period of 2
weeks. PJ consumption was associated with significant reductions in systolic BP (p=0.002) and diastolic BP
(p=0.038), but not flow mediated dilation (FMD) (p>0.05).
Serum levels of vascular cell adhesion molecule 1(VCAM1)(p=0.008) were significantly reduced by PJ while those of
E-selectin were elevated (p=0.039). However, no significant
PJ effect was observed on serum levels of intercellular adhesion molecule 1 (ICAM-1), high-sensitivity C-reactive protein (hs-CRP), lipid profile, and interleukin-6; this null effect
might be due to the short duration of the study [23]. Therefore, consumption of PJ for 2 weeks has effective hypotensive action and may also improve endothelial function.
These findings suggest PJ as a beneficial cardioprotective
supplement for hypertensive subjects, with actions extending
beyond BP reduction [23]. In an earlier (2001) study in hypertensive patients, the consumption of PJ (50 ml, 1.5 mmol
of total polyphenols per day, for 2 weeks) decreased serum
angiotensin converting enzyme (ACE) activity by 36% and
systolic BP by 5% [24]. Similar inhibitory effect (31%) of PJ
on serum ACE activity was also observed in vitro [24]. Since
a reduction in serum ACE activity was previously shown to
attenuate atherosclerosis, PJ can offer protection against
CVD, which could also be related to its inhibitory effect on
oxidative stress [24]. Another study demonstrated reduced
BP in patients with carotid artery stenosis who had consumed pomegranate juice for 3 years [25]. Ten patients were
given PJ for 1 year with 5 patients continuing consumption
for up to 3 years. Systolic BP was reduced by 21% after 1
year of PJ consumption and was not further reduced during
the 3 years of PJ use [25]. In this study, serum paraoxonase1 (PON-1) activity was increased by 83%, whereas serum
LDL basal oxidative state and LDL susceptibility to copper
ion-induced oxidation were both significantly reduced by
90% and 59%, respectively, after 12 months of PJ consumption [25]. Furthermore, serum levels of antibodies against
oxidized LDL were decreased by 19%, and in parallel serum
total antioxidant status was increased by 130% after 1 year
of PJ consumption [25]. In the control group, common carotid intima-media thickness (cIMT) increased by 9% during
1 year, whereas PJ consumption resulted in a significant
cIMT reduction, by up to 30%, after 1 year [25]. For all studied parameters, the maximal effects were observed after 1
year of PJ consumption. Further consumption of PJ, for up to
3 years, had no additional beneficial effects on IMT and serum PON-1 activity, whereas serum lipid peroxidation was
further reduced by up to 16% after 3 years of PJ consumption [25]. Total and LDL cholesterol were not significantly
affected. Regarding the effect of PJ on triglycerides (TGs),
recent data suggest an inhibitory activity of PJ on TGs biosynthesis, which could be attributed to a direct effect of PJ
on diacylglycerol acyltransferase 1 (DGAT1) activity [26].
In a larger study in subjects with moderate coronary heart
disease risk, PJ consumption (240 ml/day, n=146) or a control beverage (n=143) for up to 18 months had no significant
effect on overall cIMT progression rate, but may have
slowed cIMT progression in subjects with increased oxidative stress and abnormalities in the TG-rich lipoprotein/
high-density lipoprotein (HDL) axis [27]. Regarding HDL,
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the association of PON-1 with HDL stabilizes this antioxidant enzyme. In high-risk patients, especially those with diabetes, PON-1 dissociates from HDL and, as a consequence,
becomes less active [28]. PJ consumption augments PON-11
stability and increases its activity; this could lead to retardation of atherosclerosis development [28], especially PJ from
the "wonderful" variety of the fruit [29]. Overall, PJ has at
least 20% greatest antioxidant potency than a variety of other
antioxidant beverages, including apple juice, açaí juice,
black cherry juice, blueberry juice, cranberry juice, Concord
grape juice, orange juice, black tea, green tea and white tea
[30]. Similar benefits ofPJ consumption were observed in
diabetic patients. Indeed, PJ consumption by diabetic patients resulted in anti-oxidative effects on serum and macrophages without worsening glycemic control [31]. Moreover,
arterial stiffness of the common carotid arteries in 73 patients with at least one CVD risk factor that consumed PJ
("wonderful" variety, 240 mL/d for 1 year) showed trends to
increased elasticity in the PJ-treated group versus the placebo-treated group (who received a beverage of similar caloric content, flavor and color) [19]. However, a single dose
of PJ following a high-fat meal had no effect on reflection
index, stiffness index or diastolic BP, but lowered postprandial plasma TGs concentrations and suppressed the
postprandial increase in systolic BP following the high-fat
meal [32].
Beyond hypertension, oxidative stress is also causally related with several CVD risk factors such as diabetes, dyslipidaemia, metabolic syndrome and smoking; oxidative stress
has been proved to play a key role in the pathogenesis of
atherosclerosis [33]. Oxidized LDL (Ox-LDL) is present in
atherosclerotic lesions and in plasma from patients with
CVD, and it correlates with the presence of angiographically
documented complicated plaques [33], thus identifying patients who are at increased risk for future myocardial infarction, independently of other risk factors [34]. Since PJ contains very potent antioxidants (tannins, anthocyanins), which
are also considered potent anti-atherogenic agents, it might
attenuate atherosclerosis development by reducing oxidative
stress in these patients [34]. Indeed, human plasma obtained
from healthy subjects after 2 weeks of PJ consumption (50
mL PJ concentrate/day, equivalent to 1.5 mmol total polyphenols) demonstrated a significantly (p<0.01) decreased
susceptibility to free radical-induced lipid peroxidation, in
comparison to plasma obtained at baseline prior to PJ consumption initiation, as measured by lipid peroxides formation or by total antioxidant status in serum [31,35]. Very
recently, a study evaluated a product a new functional beverage based on a de-alcoholized red wine matrix supplemented
by a pomegranate extract. This product is expected to have
even more potent antioxidant action [36].
Regarding patients with metabolic syndrome (one of the
components of which is hypertension), it has been demonstrated that PJ exerts hypoglycaemic effects by increasing
insulin sensitivity, inhibiting -glucosidase, and modulating
glucose transporter type-4 function, but also lowers total
cholesterol and exerts anti-inflammatory effects through the
regulation of peroxisome proliferator-activated receptor
pathways [37].
     !" , numerous studies reported promising results on the anticarcinogenic, and anti-
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inflammatory properties of PJ, focusing on treatment and
prevention of cancer (mainly prostate), dental conditions,
erectile dysfunction, bacterial infections and antibiotic resistance, and ultraviolet radiation-induced skin damage [38].
In conclusion, current data suggest that long-term (at
least for 1 year) use of PJ has a beneficial effect on BP, improves endothelial function, reduces arterial stiffness and
delays or reverses the progression of atherosclerosis. These
effects could result in an improvement in CV and overall
health status. Therefore, PJ might be useful as an adjunctive
therapy for the management of hypertension on top of other
non-pharmacological interventions or drug therapy. The use
of PJ might reduce the number of drugs or their doses for
patients requiring antihypertensive drug therapy. PJ might be
more useful in patients with hypertension and high oxidative
burden such as those with diabetes, obesity, metabolic syndrome or who smoke. However, our knowledge on the CV
effects of PJ are based on studies with a small number of
patients and limitations in their design. Therefore, future
long-term well-designed studies with polyphenols-rich foods
(alone or in combination), but also with isolated phenolic
compounds would provide valuable data to establish public
health recommendations on the use of polyphenols
for health protection.
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